AbbVie stock after-hours at EUR 232.75: minus 0.47 percent versus prior close
📉 AbbVie stock closed at EUR 232.75 after-hours on September 29, 2026, down 0.47% from the prior close of EUR 233.85.
🤝 The company announced a strategic partnership with Valkai to integrate artificial intelligence into its clinical development workflow.
⚡ This collaboration aims to deploy purpose-built AI capabilities to improve efficiency and speed up insights in targeted clinical research areas.
✅ AbbVie secured FDA approval for JUVMO (tavapadon) for the treatment of adults with Parkinson's disease.
📅 The company expects to launch JUVMO for U.S. patients in October 2026 following regulatory clearance.
Bullish Signals
- AbbVie secured FDA approval for JUVMO (tavapadon), a selective D1/D5 receptor agonist, expanding its treatment options for adults with Parkinson's disease.
- The company plans to launch the newly approved drug JUVMO in the U.S. market in October 2026, creating new revenue potential in the neurology segment.
Risk Factors
- AbbVie stock declined 0.47% in after-hours trading on September 29, 2026, closing at EUR 232.75 versus a prior close of EUR 233.85.
Full Analysis
AbbVie Inc. (ABBV) traded at EUR 232.75 in after-hours trading on September 29, 2026, representing a slight decline of 0.47% against the prior close of EUR 233.85. The stock movement occurred following market hours and reflects minor volatility relative to the previous session's closing price.
In strategic developments, AbbVie announced a new partnership with Valkai, a life sciences artificial-intelligence platform, aimed at enhancing its clinical development capabilities. This collaboration is designed to deploy purpose-built AI tools across targeted areas of clinical research, with the specific goal of improving operational efficiency and accelerating the generation of critical insights for drug discovery processes.
On the regulatory front, AbbVie received approval from the U.S. Food and Drug Administration (FDA) for JUVMO (tavapadon) to treat adults with Parkinson's disease. The company plans to make this selective D1/D5 receptor agonist available to patients in the United States starting in October 2026, marking a significant expansion into its neurology portfolio.
